이식 시장 : 장기 유형별, 제품 유형, 기증자 유형별, 수술 유형별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Transplantation Market is projected to grow by USD 21.99 billion at a CAGR of 9.20% by 2032.

Transplantation is a critical pillar of modern healthcare, spanning kidney, liver, heart, lung, pancreas, intestine, tissue, corneal, hematopoietic stem cell, and emerging cell-based procedures. Demand continues to outpace supply: the WHO Global Observatory on Donation and Transplantation has reported more than 150,000 solid organ transplants annually worldwide, yet this represents only a fraction of estimated clinical need.

The market is shaped by rising chronic kidney disease, diabetes, liver failure, cardiopulmonary disease, cancer-related stem cell transplantation, and longer survival among patients with end-stage organ disease. Growth is also supported by improved immunosuppression, organ preservation technologies, donor-recipient matching, transplant diagnostics, and expanding national registries that improve transparency, traceability, and allocation efficiency.

Transformative Shifts in the Transplantation Landscape

The transplantation landscape is shifting from procedure-led care toward integrated transplant ecosystems that combine donor identification, organ recovery, perfusion, diagnostics, logistics, surgery, immunology, and lifelong post-transplant monitoring. Machine perfusion, normothermic preservation, advanced cold-chain logistics, and improved histocompatibility testing are extending the usability of higher-risk organs and creating new opportunities to improve transplant access.

At the same time, health systems are placing greater emphasis on equity, living donation safety, deceased donor optimization, and value-based outcomes. The industry is moving beyond survival as the only benchmark and increasingly measuring graft longevity, quality of life, readmission rates, rejection episodes, infection control, medication adherence, and long-term immunosuppression management.

Cumulative Impact of Artificial Intelligence in Transplantation

Artificial intelligence is becoming a high-impact enabler across transplantation, particularly in donor-recipient matching, organ viability assessment, waitlist prioritization, post-transplant risk prediction, pathology interpretation, imaging analysis, and remote patient monitoring. AI models can help identify early signs of rejection, infection, graft dysfunction, or medication non-adherence when trained on validated clinical datasets and monitored against real-world outcomes.

The cumulative impact is not limited to clinical decisions. AI-supported logistics can improve organ transport routing, reduce cold ischemia time, and support operating room coordination, while predictive analytics can strengthen donor referral workflows and post-discharge care. However, responsible adoption requires explainable algorithms, bias testing, clinical validation, cybersecurity safeguards, human oversight, and compliance with medical device and data protection regulations.

Key Regional Insights Across Transplantation Markets

North America remains one of the most advanced transplantation regions, supported by mature organ procurement organizations, national allocation systems, high clinical trial activity, and strong reimbursement infrastructure. The United States has repeatedly reported record transplant activity through national procurement and transplantation data, while Canada continues to emphasize interprovincial coordination, deceased donation improvement, living donation programs, and equitable access across geographically dispersed populations.

Europe benefits from well-established transplant networks, quality registries, cross-border collaboration, and strong leadership from countries such as Spain, the United Kingdom, Germany, France, and Italy. European programs are supported by structured donor safety rules, tissue and cell quality standards, and long-running national registries that help benchmark clinical outcomes. Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia strengthen transplant capacity, living donor programs, transplant governance, and regulatory oversight, with demand reinforced by diabetes, kidney disease, liver disease, and aging populations.

Latin America shows steady progress led by Brazil and Mexico, though access remains constrained by uneven hospital infrastructure, donor identification capacity, intensive care availability, and regional disparities. The Middle East is investing in specialist transplant centers, national donation frameworks, and self-sufficiency initiatives to reduce dependence on outbound care. Africa presents long-term potential as dialysis demand, workforce development, transplant training, tissue typing capacity, ethical donation systems, and public awareness programs expand, although many countries continue to face limitations in financing, critical care infrastructure, and post-transplant medicine access.

Key Group Insights for Strategic Transplantation Assessment

The G7 accounts for a large base of advanced transplantation capacity due to high healthcare spending, established academic medical centers, sophisticated registries, and broad availability of complex surgery, immunology, diagnostics, and post-transplant follow-up. NATO countries also represent a significant concentration of transplant infrastructure, particularly in North America and Europe, where procurement, logistics, national allocation rules, and clinical governance are comparatively mature.

The European Union supports transplantation through regulatory harmonization, safety standards, vigilance systems, traceability requirements, and cross-border collaboration for organs, tissues, and cells. BRICS nations are increasingly important because of population scale, expanding healthcare investment, rising chronic disease burden, and ongoing efforts to formalize donation systems and transplant regulation. ASEAN markets are at different stages of transplant system maturity, with Singapore, Thailand, and Malaysia advancing specialized services, while broader regional development depends on donor awareness, workforce training, and financing capacity. GCC countries are investing in transplant centers, deceased donation frameworks, and national registries to reduce outbound medical travel, improve self-sufficiency, and strengthen continuity of care for kidney, liver, and other complex transplant procedures.

Key Country Insights in Transplantation

The United States leads in transplant volume, innovation, and clinical research, with strong activity in kidney, liver, heart, lung, pancreas, intestine, tissue, and hematopoietic stem cell transplantation. Canada emphasizes equitable access, interprovincial coordination, and living donation support, while Mexico is expanding transplant capacity amid persistent gaps in deceased donation rates and regional access. Brazil is Latin America's largest transplantation system, supported by public-sector procurement, specialized centers, and national coordination, and it remains central to regional kidney, liver, heart, and corneal transplant activity.

In Europe, the United Kingdom, Germany, France, Italy, and Spain anchor advanced transplant services through national registries, specialized surgical centers, donor coordination, and long-term outcome monitoring. Spain is widely recognized for deceased donation performance and intensive care-based donor identification, while Germany and France maintain deep clinical expertise in complex organ and tissue transplantation. The United Kingdom has strong national coordination and blood, organ, tissue, and stem cell infrastructure; Italy combines national oversight with strong regional transplant networks; Spain continues to set benchmarks in donation organization; and Russia maintains transplant capacity across major urban centers, with activity concentrated in specialized hospitals.

In Asia-Pacific, China has expanded transplant governance, hospital capability, and regulatory oversight, while India is growing rapidly in kidney and liver transplantation through both public and private sector capacity. Japan remains highly specialized with a distinctive deceased donation environment and strong expertise in living donor and advanced surgical procedures. Australia maintains strong clinical quality, national coordination, and transparent reporting, and South Korea is a regional leader in advanced surgical techniques, immunology, living donor transplantation, and high-complexity hospital infrastructure.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize solutions that increase usable organ supply, shorten ischemia time, and improve long-term graft outcomes. Investments in machine perfusion, digital donor management, histocompatibility testing, molecular diagnostics, therapeutic drug monitoring, noninvasive rejection surveillance, and post-transplant remote monitoring can address both clinical and operational bottlenecks.

Strategic partnerships with transplant centers, organ procurement organizations, blood and marrow registries, diagnostics providers, logistics specialists, and public health agencies will be essential. Leaders should also build evidence packages demonstrating survival benefits, graft longevity, reduced rejection, cost-effectiveness, workflow efficiency, and lower hospital utilization to support payer adoption, clinical confidence, and regulatory review.

Research Methodology

This executive summary is based on secondary research from publicly available transplantation registries, health authority publications, peer-reviewed clinical literature, hospital network data, policy documents, and regulatory sources. Key sources typically include the WHO Global Observatory on Donation and Transplantation, national transplant registries, organ procurement and transplantation data systems, European transplant networks, national blood and transplant authorities, and regional health ministries.

The methodology triangulates procedure activity, disease burden indicators, reimbursement patterns, regulatory developments, technology adoption, donor availability, waiting list dynamics, and clinical outcomes. Insights are validated through consistency checks across multiple sources and organized to reflect market dynamics, regional variation, artificial intelligence impact, technology adoption, ethical considerations, and strategic implications for stakeholders.

Conclusion

Transplantation is entering a more data-driven, technology-enabled phase in which organ availability, graft quality, logistics precision, clinical governance, and longitudinal patient management determine market success. Demand remains structurally high because of chronic disease prevalence, aging populations, rising end-stage organ failure, and the persistent gap between patients awaiting transplantation and available donors.

Organizations that combine clinical credibility, regulatory discipline, ethical governance, equitable access strategies, and digital innovation will be best positioned to improve outcomes and support sustainable growth. The next phase of competition will be defined by measurable impact on transplant access, graft survival, operational efficiency, donor utilization, patient safety, and quality of life.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Transplantation Market, by Organ Type

• 7.1. Heart
• 7.2. Intestine
• 7.3. Kidney
• 7.4. Liver
• 7.5. Lung
• 7.6. Pancreas

8. Transplantation Market, by Product Type

• 8.1. Consumables
  • 8.1.1. Catheters
  • 8.1.2. Grafts
  • 8.1.3. Sutures
• 8.2. Devices
  • 8.2.1. Monitoring Devices
  • 8.2.2. Perfusion Devices
  • 8.2.3. Preservation Solutions
• 8.3. Implants
  • 8.3.1. Artificial Organs
  • 8.3.2. Vascular Grafts
• 8.4. Pharmaceuticals
  • 8.4.1. Antiproliferative Agents
  • 8.4.2. Calcineurin Inhibitors
  • 8.4.3. Corticosteroids
  • 8.4.4. Mtor Inhibitors

9. Transplantation Market, by Donor Type

• 9.1. Deceased Donor
• 9.2. Living Donor

10. Transplantation Market, by Procedure Type

• 10.1. Laparoscopic
• 10.2. Open
• 10.3. Robotic

11. Transplantation Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Hospitals
• 11.3. Specialty Clinics

12. Transplantation Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Transplantation Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Transplantation Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. 21st Century Medicine
• 16.2. AbbVie Inc.
• 16.3. Astellas Pharma Inc.
• 16.4. Baxter International Inc.
• 16.5. Bio-Rad Laboratories, Inc.
• 16.6. BiolifeSolutions, Inc.
• 16.7. Bristol-Myers Squibb Company
• 16.8. CHIESI Farmaceutici S.p.A.
• 16.9. Dr. Franz Kohler Chemie GmbH
• 16.10. F. Hoffmann-La Roche AG
• 16.11. Illumina, Inc.
• 16.12. Johnson & Johnson
• 16.13. Medtronic PLC
• 16.14. Merck KGaA
• 16.15. Novartis AG
• 16.16. Organ Recovery Systems, Inc.
• 16.17. Organovo, Inc.
• 16.18. OrganOx Limited
• 16.19. Pfizer Inc.
• 16.20. Plexision, Inc.
• 16.21. Sanofi S.A.
• 16.22. Teva Pharmaceutical Industries Ltd.